EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study

Choong-Kun Lee iD, Hyo Song Kim iD, Minkyu Jung iD, Hyunki Kim, Woo Kyun Bae iD, Dong-Hoe Koo iD, Hei Cheul Jeung, Sook Ryun Park, In Gyu Hwang iD, Dae Young Zang iD, Hyun Woo Lee iD, Sejung Park iD und 3 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.00971 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Choong-Kun Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Epstein-Barr Virus Infections, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study aimed to screen targeted agents as second-line treatment with a standard-of-care (SOC) controlled umbrella trial design in advanced gastric cancer (AGC). PATIENTS AND METHODS Patients with HER2-negative AGC from eight Korean cancer centers were screened for druggable targets using immunohistochemistry (IHC) and in situ hybridization, and randomly assigned to the biomarker versus control group at a 4:1 ratio. In the biomarker group, patients were treated with specific targeted agent plus paclitaxel: pan-ERBB inhibitor for epidermal growth factor receptor (EGFR) 2+/3+ patients (afatinib; EGFR cohort), PIK3Cβ inhibitor for phosphatase and tensin homolog (PTEN) loss/null patients (GSK2636771; PTEN cohort), and anti–PD-1 inhibitor for PD-L1+, deficient mismatch repair/microsatellite instability-high, or Epstein-Barr virus–related cases (nivolumab; NIVO cohort). NONE cohort in the biomarker group without predefined biomarkers and control group received SOC (paclitaxel with or without ramucirumab). The primary end point was progression-free survival (PFS), and the secondary end points were efficacy and safety. RESULTS A total of 318 patients were randomly assigned into the control (n = 64) and biomarker (n = 254; EGFR, n = 67; PTEN, n = 37; NIVO, n = 48; NONE, n = 102) groups. Median follow-up was 35 months. Median PFS and overall survival (OS) were 3.7 (95% CI, 3.1 to 4.1) and 8.6 (95% CI, 7.6 to 9.8) months in the biomarker group and 4.0 (95% CI, 3.0 to 4.6) and 8.7 (95% CI, 7.1 to 9.9) months in the control group. Afatinib addition led to marginal survival benefits to patients with EGFR 3+ compared with SOC (PFS, 4.0 v 2.2 months; P = .09), but GSK2636771 did not prolong the survival of patients with PTEN loss. Addition of nivolumab showed a durable survival benefit (median OS, 12.0 v 7.6 months; P = .08). CONCLUSION Although biomarker group did not show better survival than the control group, IHC-based screening and allocation of patients with AGC to the second-line treatment in an umbrella design were feasible for effective early screening of novel agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEpstein-Barr Virus InfectionsAntineoplastic AgentsHumansAfatinibTreatment OutcomeNivolumabHerpesvirus 4, HumanPaclitaxelErbB ReceptorsBiomarkers, TumorAntineoplastic Combined Chemotherapy Protocols

Substanzen

AfatinibNivolumabAntineoplastic AgentsPaclitaxelErbB ReceptorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Hematology-Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, South Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

ORCID-Profile: Choong-Kun Lee, Hyo Song Kim, Minkyu Jung, Woo Kyun Bae, Dong-Hoe Koo, In Gyu Hwang, Dae Young Zang, Hyun Woo Lee, Sejung Park, Chung Mo Nam, Hyun Cheol Chung, Sun Young Rha

Zitieren

APA

Lee, C. K., Kim, H. S., Jung, M., Kim, H., Bae, W. K., Koo, D. H., Jeung, H. C., Park, S. R., Hwang, I. G., Zang, D. Y., Lee, H. W., Park, S., Nam, C. M., Chung, H. C., & Rha, S. Y. (2024). Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00971

Vancouver

Lee CK, Kim HS, Jung M, Kim H, Bae WK, Koo DH, et al. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.00971

BibTeX
@article{Lee2024,
  author = {Lee, Choong-Kun and Kim, Hyo Song and Jung, Minkyu and Kim, Hyunki and Bae, Woo Kyun and Koo, Dong-Hoe and Jeung, Hei Cheul and Park, Sook Ryun and Hwang, In Gyu and Zang, Dae Young and Lee, Hyun Woo and Park, Sejung and Nam, Chung Mo and Chung, Hyun Cheol and Rha, Sun Young},
  title = {Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.00971}
}
Kostenlos starten →